Physician profile
Yanping Yu
NPI 1376555102
$3,526.31
in general payments reported to CMS, 2019-2025
19 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $531 · 2023: $290 · 2024: $1,276 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.77 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $519.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $472.49 | 2021-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $431.76 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $326.21 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $256.22 | 2024-2025 | |
| Ardelyx, INC. | $247.28 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $236.59 | 2022-2025 | Veltassa |
| Lilly USA, LLC | $234.16 | 2023-2025 | Jardiance |
| Amgen INC. | $186.54 | 2024-2025 | Krystexxa, Tavneos, Uplizna |
| Calliditas Therapeutics US INC. | $138.99 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.00 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $101.83 | 2022-2024 | Injectafer |
| Novo Nordisk INC | $70.21 | 2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $52.74 | 2022-2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $41.19 | 2024 | Gattex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $30.59 | 2024 | Terlivaz |
| Fresenius USA Marketing, INC. | $25.08 | 2024 | Velphoro |
| Fresenius USA Manufacturing, INC. | $23.53 | 2025 | |
| Akebia Therapeutics INC | $16.98 | 2024 | Auryxia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanping Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.